Crizotinib and Defactinib: Interaction Details

Brand names
Crizotinib
Xalkori
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Defactinib

We don't have a drug information page for Defactinib yet. Have a question about Defactinib? Ask a pharmacist, free →

What Happens When You Take Crizotinib With Defactinib

What can happen when they are taken together (rated Major)

Increased defactinib exposure and an increased risk of defactinib-related adverse effects

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Defactinib is a , and it should not be combined with strong or moderate . Giving defactinib together with such inhibitors raises defactinib exposure, which could heighten the risk of adverse reactions to defactinib.

A drug interaction study tested defactinib alongside itraconazole (a strong CYP3A ) at 200 mg daily for 10 days. Defactinib rose 2.2-fold and rose 3.9-fold. For M4, AUC rose 2.2-fold while Cmax fell by 6.8%.1

The Crizotinib and Defactinib Interaction, Explained

Crizotinib can raise the amount of defactinib in your body. Your body uses an enzyme called to break down defactinib, and crizotinib slows that enzyme down. With less breakdown, more defactinib stays in your blood, which can mean more side effects from it.

The size of the effect was measured with a different, stronger enzyme blocker (itraconazole), where defactinib levels rose about 4-fold. Your care team will weigh this when choosing your treatment. Please keep taking your medicines as prescribed, and talk with your pharmacist or doctor about this combination and about any new or worsening side effects.

Mechanism: Crizotinib inhibits , the pathway that metabolizes defactinib (CYP3A4 ). Expected direction: decreased , increased defactinib exposure and higher risk of defactinib adverse reactions.

  • Magnitude (surrogate data): with itraconazole 200 mg daily x10 days (strong ), defactinib rose 2.2-fold and 3.9-fold; M4 AUC rose 2.2-fold, Cmax fell 6.8%. No crizotinib-specific figure is given here.
  • Onset: unspecified. Evidence: probable. Severity: major.
  • Management: labeling advises avoiding strong or moderate CYP3A . If is unavoidable, individualize therapy and monitor closely for defactinib toxicity.

See the 1 reference behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Crizotinib and Defactinib Interact

The likely mechanism

of -mediated of defactinib

In short: Crizotinib slows CYP3A4, an enzyme that breaks down defactinib, so defactinib can build up in the body.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When One Drug Raises Another’s Level”, one chapter of our one-minute explainer. See how it works 

How to Manage the Crizotinib and Defactinib Interaction

The documented advice is to avoid combining defactinib with medicines that block , and crizotinib falls into this category. Your care team will decide whether this combination is right for you.

  • Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise.
  • Ask your pharmacist or prescriber to review this combination, and whether alternatives are an option.
  • If both are needed, your team may adjust and individualize your treatment and monitor you more closely.
  • Report any new or worsening side effects promptly.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Crizotinib or Defactinib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: AVMAPKI FAKZYNJA CO-PACK oral capsules, tablets, avutometinib oral capsules, defactinib oral tablets

    A drug interaction study found that with itraconazole (a strong ) at 200 mg daily for 10 days raised defactinib 2.2-fold and 3.9-fold. For N-desmethyl amide (M4), the major of defactinib, AUC rose 2.2-fold while Cmax fell by 6.8%.1

Crizotinib and Defactinib: Common Questions

How serious is the Crizotinib and Defactinib interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Crizotinib and Defactinib interaction managed?

The documented advice is to avoid combining defactinib with medicines that block , and crizotinib falls into this category. Your care team will decide whether this combination is right for you. Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Ask your pharmacist or prescriber to review this combination, and whether alternatives are an option. If bo… Management is individual — always follow your own care team's guidance.

Does taking Crizotinib and Defactinib at different times of day help?

No. Taking them at different times of day does not prevent this one. Crizotinib slows , an enzyme that breaks down defactinib, so defactinib can build up in the body. That change lasts while crizotinib is being taken and can continue for a while after the last dose.

Your pharmacist or prescriber can tell you how they will manage it.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Crizotinib and Defactinib Interaction

Ask in your own words about taking Crizotinib and Defactinib together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (1)

  1. Product Information: AVMAPKI(TM) FAKZYNJA(TM) CO-PACK oral capsules, tablets, avutometinib oral capsules, defactinib oral tablets. Verastem, Inc (per manufacturer), Needham, MA, 2025. DailyMed
Was this write-up helpful?

Other Serious Interactions of Crizotinib and Defactinib

Also serious with Crizotinib

Also serious with Defactinib

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Crizotinib

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.